Learn about the only option comparable to the Gold Standard for tubal patency testing.1 Attend one of our in-booth presentations with live demonstrations during the American Society for Reproductive Medicine (ASRM) 2022 Congress and Expo. This year’s congress will take place at the Anaheim Convention Center in California from October 24 – 26, 2022.

Join professional colleagues in learning about the advantages of the HyFoSy procedure. RSVP for one of our in-booth presentations and/or schedule a one-on-one meeting with an ExEm® Foam Team member for information on:

  • In-clinic HyFoSy training opportunities
  • HyFoSy ultrasound imaging samples
  • New programs to benefit your clinic(s) and patients
  • Product samples

Click here to RSVP: https://hubs.la/Q01mdn_B0

 About the ASRM 2022 Scientific Congress
The theme of the 2022 Scientific Congress of the American Society for Reproductive Medicine is “Genes, Gametes, and Genetics: What Will the Future Hold?” Events and discussions will focus on the scope of reproductive medicine ranging from puberty to menopause, including all genders, while having a focus that is both molecular and macroscopic.

ASRM is a multidisciplinary organization dedicated to the advancement of the science and practice of reproductive medicine. The Society accomplishes its mission through the pursuit of excellence in education and research and through advocacy on behalf of patients, physicians, and affiliated health care providers. The Society is committed to facilitating and sponsoring educational activities for the lay public and continuing medical education activities for professionals who are engaged in the practice of and research in reproductive medicine. To learn more about ASRM and the 2022 Scientific Congress and Expo, visit https://www.asrm.org

About ExEm® Foam (air polymer-type A) intrauterine foam
ExEm® Foam ((air polymer-type A) intrauterine foam) is an innovative, FDA-approved product that offers a less invasive ultrasound procedure, a highly accurate alternative to other tubal patency assessment procedures, like laparoscopy or X-ray HSG. The contrast agent allows for easy recognition of tubal patency using the Foam procedure. During the tubal patency procedure, the foam is infused into the uterus by a healthcare professional to allow for visual assessment of fallopian tubes. If the tubes are patent the foam will appear as a thin, bright white line within the fallopian tubes and spill over the ovaries and into the peritoneal cavity when visualized with ultrasound. If the white line does not appear, the fallopian tubes might be occluded or blocked.

IMPORTANT SAFETY INFORMATION
ExEm® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting.

Click here for full prescribing information.

‍About ExEm® Foam Inc
ExEm® Foam Inc is focused on providing solutions to simplify infertility diagnosis and enhance the fertility journey. Drawing on its years of experience, the team develops innovative products that better meet the needs of today’s patient and healthcare professional. ExEm® Foam, the company’s first FDA-approved product, is indicated as a contrast drug for hysterosalpingo foam sonography, also known as HyFoSy, to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. ExEm® Foam has been used in more than 500,000 tubal patency procedures worldwide since it first launched in Europe in 2011. ExEm® Foam Inc is headquartered in Nashville, TN.

For more information, please visit www.exemfoam.com.

¹ Devine, K, et al. Modern pre-ART uterine and tubal assessment. Fertil Steril 2022